Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928359 | 1.00 | POLB (0.42) | POLBCA2CAMK2AALDH1A1KMT2A | |
| SCHEMBL6946769 | 1.00 | POLB (0.42) | POLBCA2CAMK2AALDH1A1KMT2A | |
| SCHEMBL9781967 | 0.97 | — | — | |
| SCHEMBL10663300 | 0.92 | — | — | |
| SCHEMBL3043655 | 0.85 | — | — | |
| SCHEMBL27861148 | 0.76 | CA2 (0.39) | CA2ALDH1A1KMT2ATSHRHTT | |
| SCHEMBL7976967 | 0.76 | POLB (0.32) | POLBALDH1A1KMT2AHTTTDP1 | |
| SCHEMBL10721635 | 0.74 | POLB (0.39) | POLBCA2CAMK2AALDH1A1AKR1B1 | |
| SCHEMBL10665467 | 0.74 | FFAR1 (0.42) | CA2ALDH1A1LMNATHRATHRB | |
| SCHEMBL3608741 | 0.72 | FFAR1 (0.41) | CA2ALDH1A1LMNATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116135229-A | Application of hypocrellin-containing derivative with both peri-position and 2-position being simultaneously substituted in preparation of photodynamic anti-tumor drugs | 中国科学院理化技术研究所 | 2023-05-19 | — | — | CN | claimed |
| EP-3680230-B1 | HYPOCRELLIN DERIVATIVE SUBSTITUTED BOTH IN A PERI-POSITION AND IN 2-POSITION BY AMINO, PREPARATION METHOD, AND APPLICATION THEREOF | TECHNICAL INST OF PHYSICS AND CHEMISTRY OF THE CHINESE ACADEMY OF SCIENCES (CN) | 2022-11-02 | — | — | EP | claimed |
| US-20210145968-A1 | HYPOCRELLIN DERIVATIVE SUBSTITUTED BOTH IN A PERI-POSITION AND IN 2-POSITION BY AMINO, PREPARATION METHOD, AND APPLICATION THEREOF | Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences (CN) | 2021-05-20 | — | — | US | claimed |
| CN-109456210-B | Hypocrellin peri-and 2-amino-substituted derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2020-09-25 | — | — | CN | claimed |
| EP-3680230-A1 | DERIVATIVES OF HYPOCRELLIN WITH PERI-POSITION AND 2-POSITION SIMULTANEOUSLY SUBSTITUTED BY AMINO GROUPS | Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences (CN) | 2020-07-15 | — | — | EP | claimed |
| CN-109456210-A | Hypocrellin peri-and 2-amino-substituted derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2019-03-12 | — | — | CN | claimed |
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | claimed |
| CN-102186830-A | New benzimidazole derivatives | HOFFMANN LA ROCHE | 2011-09-14 | — | — | CN | claimed |
| EP-2350022-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| WO-2010043513-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | claimed |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | claimed |
| EP-4328276-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328275-A1 | ANTI-FOULING COATING MATERIAL COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328274-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4306599-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-01-17 | — | — | EP | disclosed |
| EP-0861247-B1 | NOVEL IMIDAZOLE N-BENZYLDIOXOL DERIVATIVES, METHOD FOR PREPARING SAME, RESULTING INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND USE OF SAID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | AVENTIS PHARMA SA (FR) | 2009-10-07 | — | — | EP | disclosed |
| CN-1675180-A | Indole, indazole, and benzazole derivative | SUMITOMO PHARMA (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1049678-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | Nanogen Recognomics GmbH (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999015509-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145968-A1 | HYPOCRELLIN DERIVATIVE SUBSTITUTED BOTH IN A PERI-POSITION AND IN 2-POSITION BY AMINO, PREPARATION METHOD, AND APPLICATION THEREOF | HCCS, PPOX, AAAS | POLB 1296/4885CA2 382/4885CAMK2A 2902/4885 |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | CYP2B6, CYP3A4, CYP2C19 | POLB 2846/4885CA2 1174/4885CAMK2A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.